Figure 1. Overall survival of the 23 patients, and according to primary tumor site, since liver surgery.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website https://www.wjon.org |
Original Article
Volume 13, Number 6, December 2022, pages 359-364
Will Patients With Liver Metastasis From Aggressives Cancers Benefit From Surgical Resection?
Figure
Tables
| aCalculated on patients with synchronous metastatsis. BMI: body mass index; SD: standard deviation; LM: liver metastasis; ASA: American Society of Anesthesiologists. | |
| Sex ratio (M/F) | 2.8 (17/6) |
| Median age (range) | 67 (26 - 80) |
| Mean BMI (± SD) | 23.1 (± 4.63) |
| Performance status (before liver surgery) (%) | |
| 0 - 1 | 23 (100) |
| ≥ 2 | 0 |
| ASA score (%) | |
| 1 | 3 (13) |
| 2 | 18 (78) |
| 3 | 2 (9) |
| Primary tumor etiology (%) | |
| Pancreatic ductal adenocarcinoma | 10 (43) |
| Esophagus/gastric cancer | 9 (39) |
| Non-small cell lung cancer | 4 (18) |
| Synchronous LM (%) | 9 (39) |
| Median delay initial diagnosis - LM diagnosis (months) (range) | 12 (0 - 67) |
| Median delay LM diagnosis - liver surgery (months) (range) | 10 (8 - 61) |
| Liver metastasis | |
| Median number (range) | 1 (1 - 10) |
| Mean size of the biggest LM (mm) (± SD) | 38.3 (± 22.03) |
| Unilobar (%) | 16 (70) |
| Chemotherapy prior to surgery after LM diagnosis | |
| Median number of lines (range) | 1 (1 - 3) |
| Objective response to chemotherapy (>10%) (%) | 13 (57) |
| Surgery | |
| Major hepatectomy (%) | 9 (39) |
| Minor hepatectomy (%) | 8 (35) |
| Minor hepatectomy + local destruction (%) | 4 (17) |
| Local destruction (%) | 2 (9) |
| Primary tumor resection combined with LM resectiona (%) | 5 (56) |
| Mean intraoperative blood loss (mL) (± SD) | 216.7 (± 163.8) |
| Mean operative duration (min) (± SD) | 201 (± 115.8) |
| Overall morbidity (%) | 8 (35) |
| Severe morbidity (%) | 3 (13) |
| 90-day mortality (%) | 1 (4.3) |
| Median lenght of hospital stay (days) (range) | 11 (4 - 34) |
| Readmission (%) | 3 (13) |
| Adjuvant chemotherapy (%) | 4 (17) |
| Patient | Etiology | Recurrence | Liver recurrence | Status | Survival* (months) | Cancer-related death |
|---|---|---|---|---|---|---|
| *From liver surgery. NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma; EGC: esophagus/gastric cancer. | ||||||
| 1 | EGC | No | No | Dead | 1 | No |
| 2 | EGC | Yes | No | Alive | 19 | - |
| 3 | NSCLC | No | No | Alive | 19 | - |
| 4 | EGC | No | No | Alive | 160 | - |
| 5 | EGC | Yes | Yes | Dead | 16 | Yes |
| 6 | NSCLC | No | No | Alive | 87 | - |
| 7 | EGC | Yes | Yes | Dead | 24 | Yes |
| 8 | EGC | No | No | Dead | 4 | Yes |
| 9 | EGC | Yes | Yes | Dead | 32 | Yes |
| 10 | EGC | Yes | Yes | Dead | 17 | Yes |
| 11 | PDAC | Yes | Yes | Dead | 31 | Yes |
| 12 | PDAC | Yes | Yes | Dead | 10 | Yes |
| 13 | PDAC | Yes | Yes | Dead | 28 | Yes |
| 14 | PDAC | No | No | Alive | 36 | - |
| 15 | EGC | Yes | Yes | Dead | 16 | Yes |
| 16 | PDAC | Yes | Yes | Dead | 6 | Yes |
| 17 | PDAC | Yes | Yes | Dead | 10 | Yes |
| 18 | NSCLC | No | No | Alive | 8 | - |
| 19 | PDAC | Yes | Yes | Dead | 5 | Yes |
| 20 | NSCLC | No | No | Alive | 22 | - |
| 21 | PDAC | No | No | Alive | 7 | - |
| 22 | PDAC | Yes | No | Alive | 18 | - |
| 23 | PDAC | No | No | Alive | 14 | - |